CalciMedica raises ~$15M in private placement; FDA clears continued Auxora development

CalciMedica, Inc.

Private placement of 18.7M units at $0.8033 each; gross proceeds ~$15M, up to $34M additional from warrant exercises.
FDA reviewed KOURAGE trial protocol amendment and interim safety data; no comments or questions, dosing may resume.
Insiders including CEO, CBO, CMO, and major holders purchase ~6.9M units.
Plans Phase 1b study of Auxora in pulmonary arterial hypertension (PAH) with data expected mid-2027.
IND clearance for oral CM5480 anticipated mid-2027; cash runway into second half of 2027.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.